3 citations
,
October 2021 in “Brain Sciences” Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
76 citations
,
June 2018 in “EMBO Reports” YAP and TAZ proteins are necessary for the development of two types of skin cancer.
4 citations
,
April 2016 in “Journal of Dermatology Research and Therapy” Anti-androgens are safe and effective for treating moderate to severe adult female acne.
2 citations
,
August 2022 in “World Journal of Clinical Cases” Albumin and prednisone improved symptoms in a woman with Cronkhite-Canada syndrome, revealing potential genetic causes.
37 citations
,
August 2016 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.
2 citations
,
November 2011 in “InTech eBooks” Most adrenal cortex tumors are benign and non-secreting, but proper diagnosis and treatment are important due to the rare possibility of cancer.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” The use of Diane-35 and its generics significantly decreased in the Netherlands.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
1 citations
,
August 2022 in “American Journal of Tropical Medicine and Hygiene” Scalp abscesses can occur after hair loss treatments and may be caused by Mycobacterium abscessus.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
June 1985 in “Journal of the American Academy of Dermatology”
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
45 citations
,
February 2018 in “Journal of basic and clinical physiology and pharmacology/Journal of basic & clinical physiology & pharmacology” *Acorus calamus* has many medicinal benefits but needs more safety research.
34 citations
,
March 2012 in “Circulation” Bridging anticoagulation may raise post-surgery bleeding risks.
11 citations
,
January 2022 in “Experimental Dermatology” Severe CCCA may be biologically and clinically different from milder forms.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
5 citations
,
October 2022 in “Biology” CAP1 helps Arabidopsis plants grow better under ammonium stress.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Botulinum toxin type A did not help regrow hair in severe alopecia cases.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
The combined treatment increased hair density in most patients with Androgenetic Alopecia.
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.